Table 2 Sensitivity of native leukemia blasts in response to THC
Patient No. | Phenotype | THC response | ||
|---|---|---|---|---|
Entity | lineage dependency is marked (+) aberrantly expressed antigens are separately indicated | % viable cells at 50 μM | ||
T-lymphatic | B-lymphatic | myeloid | ||
AML-1 | ||||
sAML (MDS) | N/A | N/A | + | 100 |
AML-2 | ||||
AML, FLT3-ITD | − | − | + | 100 |
AML-3 | ||||
AML NOS | (CD3) | − | + | 100 |
AML−4 | ||||
APL | − | − | + | 99 |
AML-5 | ||||
AML, FLT3-ITD | − | − | + | 96 |
AML-6 | ||||
AML, FLT3-ITD | − | CD19 | + | 91 |
AML-7 | ||||
AML NOS (M0) | − | − | + | 89 |
AML-8 | ||||
AML, FLT3-ITD | − | − | + | 88 |
AML-9 | ||||
N/A | N/A | N/A | + | 69 |
AML-10 | CD7 | |||
AML, FLT3-ITD | CD56 | − | + | 50 |
AML-11 | CD7 | |||
sAML (MDS) | CD5 | − | + | 46 |
AML-12 | (CD7) | |||
AML NOS (M0) | (CD5) | − | + | 33 |
AML-13 | CD7 | |||
CBF AML | CD5 | − | + | 20 |
ALL-1 | ||||
(c) B-ALL | − | + | − | 97 |
ALL-2 | CD33 | |||
pre B-ALL | − | + | CD13 | 96 |
ALL-3 | ||||
(c) B-ALL | − | + | CD33 | 94 |
ALL-4 | ||||
pre-B-ALL | − | + | − | 82 |
ALL-5 | ||||
(c) B-ALL | − | + | − | 55 |
ALL-6 | ||||
Cortical T-ALL | + | CD79 | − | 55 |
ALL-7 | ||||
(c) B-ALL | − | + | − | 54 |
ALL-8 | + | CD33 | ||
pre B-ALL | − | CD10 | CD13 | 53 |
ALL-9 | ||||
(c) B-ALL | − | + | − | 48 |
ALL-10 | ||||
(c) B-ALL | − | + | − | 43 |
ALL-11 | ||||
Cortical T-ALL | + | − | − | 38 |
ALL-12 | CD33 | |||
(c) B-ALL | − | + | CD13 | 37 |
ALL-13 | CD56 | |||
pre B-ALL | CD1a | + | CD13 | 12 |